Ginkgo Bioworks (DNA) announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health – ARPA-H – Computational ADME-Tox and Physiology Analysis for Safer Therapeutics program, or CATALYST. The collaboration, Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation, aims to develop a revolutionary computational platform for drug safety. As part of this team, Ginkgo will be leveraging its ‘Datapoints’ platform for perturbation response profiling to generate high-quality, high-throughput, structured data sets to support AI model training, including small molecule drug and genetic perturbations spanning multiple cell and tissue types. Readouts will include cell type-specific toxicity endpoints, DRUG-seq transcriptomics, and cell painting.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
- Ginkgo Bioworks awarded four-year, up to $47M contract from EMSL
- Private Markets: Prediction market platform Kalshi secures $300M
- Private Markets: Anthropic to invest $50B in computing infrastructure
- Ginkgo Bioworks Earnings Call: Mixed Sentiments and Strategic Moves
- Ginkgo Bioworks Reports Q3 2025 Financial Results